In 1999, approximately 18.4 million patients in the seven major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan) suffered from atopic dermatitis (AD), 3.5 million experienced urticaria (hives), and 11 million had psoriasis. These three inflammatory skin disorders significantly affect patients' quality of life; the majority of patients have cyclical flares that require medical attention, resulting in major expenditures over a patient's lifetime.

(Photo: )

Allergic/Inflammatory Skin Disorders is a new study published by Decision Resources, Inc. In this study, we review the epidemiology of AD, urticaria, and psoriasis in the seven major pharmaceutical markets, describe what is known of the etiology and pathophysiology of these disorders with an emphasis on mechanisms that may be exploited in current or emerging therapies, and project sales of prescription drugs to treat these inflammatory skin disorders over the 1999-2009 forecast period.

In 1999, sales of prescription drugs for AD reached approximately $564 million in the seven major markets. A significant improvement over the topical corticosteroids currently used to treat AD may be the topical immunomodulators, the only major drug class that should significantly affect the AD market during our forecast period. This class consists of Fujisawa's tacrolimus, as well as Novartis's pimecrolimus, now in Phase III trials in the United States and Europe. We estimate that by 2009, sales for AD will reach $1.2 billion-primarily as a result of an increased prevalence and the introduction of topical tacrolimus. We do not anticipate much growth in sales of prescription drugs for urticaria over our forecast period as a result of a stable prevalence rate and a nearly empty drug pipeline. Biological therapies (notably Biogen's LFA3TIP and its main competitor, Genentech/Xoma's hu1124) are expected to be the breakthrough treatments for psoriasis. Both of these drugs are in Phase III trials in the United States and are expected to launch in late 2002.

Allergic/Inflammatory Skin Disorders is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Contact: Frank Sama, 781.487.3753 (telephone), 781.487.5750 (fax), or (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or (e-mail).

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing industry trends in the international health care and pharmaceutical industries.


AP Archive:

PRN Photo Desk, 888-776-6555 or 201-369-3467

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc, 781-487-3753

New Decision Resources Study Evaluates the Potential Impact of Angiogenesis Inhibitors Over the Next Decade

View Now